SMScott P. Morton

Scott P. Morton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Scott P. Morton has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions

    by Scott P. Morton, Joshua L. Phillips

    SARS-CoV-2 is a novel virus that crossed over into humans in 2019 and declared a pandemic in early 2020. To understand how the virus infects a new host, we need to understand the mechanistic functions involved with the binding process. To address this need, we generate homology models of SARS-CoV-2 spikes as monomer and trimer to determine the feasibility of reduced computational requirements by using monomer structures. We further generate homology models of the conserved region of SARS-CoV-2 spike subunit s1 noted as the receptor binding domain (RBD) and the human angiotensin-converting enzyme 2 (ACE2). To determine functional breadth of spike monomer, trimer and RBD in relation with ACE2, we apply Coulombs Law to determine an electric force between combinations with ACE2 across the range of pH from 3.0 to 9.0 in 0.1 increments. The results indicate that spike trimer should be used to determine mechanistic binding function and these data indicate that variations of spike sequence influence breadth of function. Our results also indicate the RBD has a broader range of function across pH compared to spike trimer, but is influenced by the range of function presented by the spike trimer.

  • Open Access

    Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions

    by Scott P. Morton, Joshua L. Phillips

    SARS-CoV-2 is a novel virus that is presumed to have emerged from bats to crossover into humans in late 2019. As the global pandemic ensues, scientist are working to evaluate the virus and develop a vaccine to counteract the deadly disease that has impacted lives across the entire globe. We perform computational electrostatic simulations on multiple variants of SARS-CoV-2 spike protein s1 in complex with human angiotensin-converting enzyme 2 (ACE2) variants to examine differences in electrostatic interactions across the various complexes. Calculations are performed across the physiological pH range to also examine the impact of pH on these interactions. Two of six spike protein s1 variations having greater electric forces at pH levels consistent with nasal secretions and significant variations in force across all five variants of ACE2. Five out of six spike protein s1 variations have relatively consistent forces at pH levels of the lung, and one spike protein s1 variant that has low potential across a wide range of pH. These predictions indicate that variants of SARS-CoV-2 spike proteins and human ACE2 in certain combinations could potentially play a role in increased binding efficacy of SARS-CoV-2 in vivo .


  • Open Access

    The Molecular Basis of pH-Modulated HIV gp120 Binding Revealed

    by Scott P Morton, Julie B Phillips, Joshua L Phillips

    Decades of research has yet to provide a vaccine for HIV, the virus which causes AIDS. Recent theoretical research has turned attention to mucosa pH levels over systemic pH levels. Previous research in this field developed a computational approach for determining pH sensitivity that indicated higher potential for transmission at mucosa pH levels present during intercourse. The process was extended to incorporate a principal component analysis (PCA)-based machine learning technique for classification of gp120 proteins against a known transmitted variant called Biomolecular Electro-Static Indexing (BESI). The original process has since been extended to the residue level by a process we termed Electrostatic Variance Masking (EVM) and used in conjunction with BESI to determine structural differences present among various subspecies across Clades A1 and C. Results indicate that structures outside of the core selected by EVM may be responsible for binding affinity observed in many other studies and that pH modulation of select substructures indicated by EVM may influence specific regions of the viral envelope protein (Env) involved in protein-protein interactions.


  • Open Access

    Sub-Class Differences of PH-Dependent HIV GP120-CD4 Interactions

    by Scott P. Morton, Jonathan Howton, Joshua L. Phillips


  • High-throughput structural modeling of the HIV transmission bottleneck

    by Scott P. Morton, Julie B. Phillips, Joshua L. Phillips

    After three decades of research on human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS), a vaccine has yet to be discovered. Most theoretical and experimental work on HIV vaccines has focused on the relevant molecular interactions at systemic pH levels, but HIV is typically transmitted sexually at mucosal pH levels. We previously developed a computational approach for calculating pH-sensitivity which predicted optimal transmission at mucosal pH levels, and was validated by experimental electrophoretic measurements and envelope protein binding assays. We have recently augmented this approach using a unique combination of protein dynamical modeling, parallel computation, and data compression tools which enable high-throughput calculations. The resulting fully-automated pipeline was capable of predicting pH sensitivity for a recent study involving more than 250 unique HIV envelope proteins utilizing approximately 1 million individual electrostatic surface calculations. We provide strong evidence that supports the previous hypothesis of a computational approach to determining the pH sensitivity of HIV envelopes. Furthermore, a PCA-based indexing method is proposed that allows for a comparison of biomolecular structures in terms of electrostatic pH sensitivity. We utilize the results to predict highly transmissible HIV variants with implications for vaccine design and efficacy.